Latest news with #GBP
Yahoo
14 hours ago
- Automotive
- Yahoo
Nissan to raise JPY 1 trillion (US$7bn) to pay debt
Nissan Motor Company is looking to raise up to JPY 1 trillion (US$ 7 bn) this year from the issuance of new corporate bonds and by selling assets, as it faces massive bond redemptions and restructuring costs, according to local reports citing a company source. The struggling Japanese automaker is understood to be facing bond redemptions worth around JPY 780 billion in the current fiscal year (FY2025), ending on 31st March 2026. The company is also facing substantial restructuring costs, after it announced plans to reduce its number of global vehicle production plants from 17 to 10 by FY2027, cutting around 20,000 jobs. As well as issuing new convertible bonds worth JPY 630 billion, Nissan is also looking to sell non-core assets including shares in affiliated companies and real estate assets. This includes selling and leasing back its head office building in Yokohama and selling properties in the US. The automaker also plans to sell part of its 15% stake in its Alliance partner Renault and its entire shareholding in battery manufacturer AESC Group this year. Separate reports suggested Nissan is looking to secure a GBP 1 bn loan guaranteed by UK Export Finance, a British government-linked institution, to help safeguard its UK manufacturing operations. Among the expected plant closures are facilities in Japan, Mexico, and South Africa. Nissan is understood to be aiming to raise a large proportion of the funds in the next few months. "Nissan to raise JPY 1 trillion (US$7bn) to pay debt" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Form 8.3 - AXA INVESTMENT MANAGERS: ALPHA GROUP INTERNATIONAL PL
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: AXA Investment Managers S.A. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Alpha Group International plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 28 May 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 0.2p ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 712,276 1.68 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 712,276 1.68 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/Sale Number of securities Price per unit 0.2p ordinary Sale 2,340 GBP 30.11 (b) Cash-settled derivative transactions Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state 'none' None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NODate of disclosure: 29 May 2025 Contact name: Anthony GILSOUL Telephone number*: +33 1 44 45 97 54 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit. The Code can be viewed on the Panel's website at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hindu
5 days ago
- Business
- The Hindu
U.K. flags new Indian market for Scottish salmon trade after FTA
The U.K. Government has flagged the unlocking of the Indian market for Scottish salmon following the Free Trade Agreement (FTA) with India, finalised earlier this month and expected to be formally signed off in the coming weeks. Downing Street has this week been highlighting benefits of the India-U.K. FTA and other trade pacts struck in its wake with the U.S. and European Union (EU) in an effort to showcase the sectors and regions across the United Kingdom set to benefit. 'These trade deals deliver long term security for people in Scotland. They will create opportunities for more seamless trade and attract inward investment to grow the economy, making a difference to people's lives,' Prime Minister Keir Starmer said in a statement. 'These changes will be felt everywhere, whether it's lower food prices at the checkout, more choice for consumers and higher living standards that will improve livelihoods across Scotland,' he said. Downing Street noted that the FTA had 'unlocked a new salmon market through our deal with India, with tariffs dropping from 33% to 0%'. 'Securing frictionless access to key markets such as the EU, along with expanding opportunities in India, is crucial to protect our producers from unnecessary barriers like tariffs and red tape,' said Tavish Scott, chief executive of Salmon Scotland, the key representative of the sector. 'Ministers rightly recognise salmon as the jewel in the crown of our world-class produce and its vital role in the economy of coastal communities and across the U.K.,' he said. However, in Scotland, the spotlight remains on the whisky industry which is set to see tariffs for exports to India slashed significantly over the next decade following what the U.K. has dubbed as a 'landmark deal' — agreed on May 6 and expected to add an extra GBP 25.5 billion annually in the long run to the current two-way trade of GBP 41 billion. Under the pact, Scottish distillers will immediately see tariffs halved from 150% to 75% and eventually to just 40% over the next decade. U.K. Business and Trade Secretary Jonathan Reynolds said, 'The three landmark deals secured this month with the U.S., India, and the EU have shown this government is serious about striking the deals that our businesses want and need. 'For Scottish businesses, these deals will mean stability and jobs protected as they seize new opportunities to sell to some of our biggest trading partners." "From our world-renowned whisky distilleries to our cutting-edge green energy sector, Scotland has so much to offer international markets... By securing better access to the European Union, United States and India, we're creating real opportunities for Scottish businesses to grow, supporting jobs in communities from the Highlands to the Borders,' added Secretary of State for Scotland Ian Murray. At the Indian end, leading Goa-based whisky producer John Distillers welcomed the India-U.K. FTA as a "significant step" towards strengthening bilateral trade and economic cooperation between the two countries. 'This may have a short-term impact on Indian products in India, however, we are confident about the quality of our products and believe we can rise to the challenge,' the makers of Paul John whisky said in a statement. 'We also hope that this deal will allow better ease of business for Indian products in the U.K.. It is crucial to ensure that both nations maintain a level playing field, safeguarding the interests of domestic industries and promoting fair competition,' it noted. Until further details of the FTA emerge, the Indian distiller said it plans to continue to 'build awareness and availability' of its portfolio in the U.K. Other industries boosted by the FTA include soft drinks and food that the UK government says will 'ramp up' Scotland's export economy.
Yahoo
5 days ago
- Business
- Yahoo
ANGLE PLC (ANPCY) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Revenue Growth: 31% increase in 2024 compared to 2023. Gross Margin: Maintained at approximately 62%. Operating Expenditure: Reduced by 21%. Net Loss Reduction: Decreased by 29%. Cash Runway: GBP11.6 million, lasting into Q1 2026. Fundraising: Raised GBP9.3 million gross in June 2024. Pharma Contracts: Secured three large pharma contracts and one large biopharma contract. Potential Revenue from Trials: GBP1 million to GBP4 million for Phase 2 trials; GBP15 million to GBP45 million for Phase 3 trials. Companion Diagnostic Revenue Potential: Estimated at GBP20 million annually per program. Warning! GuruFocus has detected 2 Warning Signs with ANPCY. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ANGLE PLC (ANPCY) achieved a 31% growth in revenues for 2024 compared to 2023, despite adverse market conditions. The company successfully secured three large pharma contracts and one large biopharma contract, with all progressing well and concluding successfully. ANGLE PLC (ANPCY) developed a new DNA dual analysis method, offering unique insights by analyzing both living cancer cells and fragments of dead cells. The company reduced operating expenditure by 21%, contributing to a 29% reduction in losses. ANGLE PLC (ANPCY) has over 100 peer-reviewed publications from independent cancer centers validating the effectiveness of its Parsortix system. There are delays in decision-making from large pharma companies, affecting the timing of potential contracts. The company faces challenges due to the tightening funding environment, impacting smaller biopharma companies and delaying some projects. Uncertainty in research funding, particularly in the US, is causing delays in purchasing decisions from research institutions. The company is experiencing delays in the procurement process in Europe, even when they are the preferred vendor. ANGLE PLC (ANPCY) faces competition from established methods like circulating tumor DNA (CT-DNA) analysis, requiring significant market education efforts. Q: Can you give us a sense of how discussions with potential medtech partners are going and the size of the opportunity compared to pharma? A: Andrew Newland, Chief Executive, explained that while pharma has a defined process for clinical trials, medtech opportunities, though fewer, can be substantial. Medtech companies are interested in using Parsortix for repeat testing, which could significantly expand their revenue opportunities. The cost of tissue biopsy in metastatic breast cancer is high, and Parsortix offers a cheaper alternative. Q: Have you seen evidence of project cancellations or delays affecting the business? A: Ian Griffiths, Chief Financial Officer, noted that there have been some delays, such as Eisai handing back a project to BlissBio. This creates uncertainty, but discussions with BlissBio are ongoing. The pipeline is building, but decision-making has been slower due to market conditions. Q: Does your cash runway through Q1 2026 assume further cost reductions? A: Ian Griffiths stated that while they continue to manage costs, investments in the clinical lab are necessary to meet the requirements of large clients like AstraZeneca. They aim to keep the cost base tight while ensuring they have the capacity to deliver. Q: Is there a Parsortix product development pipeline, and what does it look like? A: Andrew Newland mentioned that the focus is on developing uses for cancer cells rather than the instrumentation itself. The Parsortix system is stable, and development work is centered on methods to analyze cancer cells, funded mainly by customers. Q: Are large pharma opportunities more about educating them on CTC technology or competition with CT-DNA? A: Andrew Newland explained that educating pharma about CTCs is crucial. Some may not be familiar with CTCs or have had past experiences with older systems. Demonstrating the advantages of Parsortix and providing data is key to gaining their interest. Q: How are tariffs affecting your business? A: Ian Griffiths noted that tariffs in the US are passed directly to customers, as Angle has a unique offering that cannot absorb these costs. Customers accept this as part of dealing with Angle. Q: Do you have visibility on when funding for basic research might open up again? A: Ian Griffiths stated that there is uncertainty due to potential budget cuts in the US. Some institutions may secure funds from other sources, but government institutions might struggle, affecting their ability to fund projects. Q: Do you have visibility on when large pharma like AstraZeneca will make decisions? A: Ian Griffiths acknowledged the challenge in predicting timing. While the pipeline is strong, uncertainty in the environment means they must be cautious in their expectations. Revenue recognition will also be spread over time once deals are signed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Form 8.3 - [Craneware]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: Danske Bank A/S (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Craneware PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 27 May 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Equity Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 537 041,00 1,52 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 537 041,00 1,52 All interests and all short positions should be of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Equity Sale 1000 20.4546 GBP (b) Cash-settled derivative transactions Class of relevant security Product descriptione.g. CFD Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Typee.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product descriptione.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealinge.g. subscription, conversion Details Price per unit (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state 'none' None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NODate of disclosure: 28 May 2025 Contact name: Kotryna Cinciuke Telephone number*: +37060405825 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit. The Code can be viewed on the Panel's website at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
